OBESITYWEEK OPENING KEYNOTE SPEAKER

TUESDAY, NOV 13, 8:00 AM | View Session Information

We will begin an amazing conference with Dr. Steven Nissen.

Steven E. Nissen, MD

Chairman of the Robert and Suzanne Tomsich Department of Cardiovascular Medicine at Cleveland Clinic

Steven E. Nissen MD is Chairman of the Department of Cardiovascular Medicine at the Cleveland Clinic and Professor of Medicine at the Cleveland Clinic Lerner College of Medicine at Case Western Reserve University. In 2006-2007 he served as President of the American College of Cardiology (ACC), the professional society representing American cardiologists.


ASMBS INTEGRATED HEALTH KEYNOTE SPEAKER

TUESDAY, NOV 13, 1:30 PM | View Session Information

Randy J. Seeley

Henry King Ransom Endowed Professor of Surgery

Dr. Randy Seeley is the Henry K. Ransom Endowed Professor of Surgery at the University of Michigan School of Medicine. He also serves as the director of the NIH-funded Michigan Nutrition Obesity Research Center (MNORC). His scientific work has focused on the actions of various peripheral hormones in the CNS that serve to regulate food intake, body weight and the levels of circulating fuels.


ASMBS MASON LECTURER

WEDNESDAY, NOV 14, 10:30 AM | View Session Information

Harvey J. Sugerman, MD

Emeritus Professor of Surgery, Virginia Commonwealth University

Dr. Sugerman received his medical degree from Thomas Jefferson University School of Medicine in 1966, served as a Medical Intern and then Surgical Resident at the Hospital of the University of Pennsylvania, which he completed in 1973. He was a Lieutenant Colonel in the U.S. Army. After the Army he spent two years in private practice in Allentown, Pa. and then joined the Medical College of Virginia faculty, where he remained for 28 years, and became the David Hume Professor of Surgery, Chairman of the General and Trauma Surgery Division and Interim Chair of the Department of Surgery. Dr. Sugerman retired from clinical practice in December, 2003.

He has published over 240 manuscripts in peer-reviewed journals, 20 books and 55 book chapters. He was President of the Western Trauma Association and the American Society for Metabolic and Surgery. He received a “Lifetime Achievement Award” in 2010 from the ASMBS. He has been the Editor-in-Chief of Surgery for Obesity and Related Diseases and now shares this roll with Raul Rosenthal.

He and his wife, Betsy, live in Sanibel, Florida. They have four children and 9 grandchildren who live in New York City, Los Angeles, Park City, Utah and Atlanta, Georgia.


TOS KEYNOTE SPEAKER

THURSDAY, NOV 15, 9:45 AM | View Session Information

Daniel J. Drucker, MD

Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital

Dr. Drucker received his MD from the University of Toronto in 1980, and is currently Professor of Medicine and the Banting and Best Diabetes Centre-Novo Nordisk Chair in Incretin Biology at the University of Toronto, and a Senior Scientist at the Lunenfeld-Tanenbaum Research Institute at Mt. Sinai Hospital. His laboratory studies the molecular biology and physiology of gut hormones with a focus on the glucagon-like peptides. Dr. Drucker and colleagues were the first to publish that GLP-1(7-37) directly augments glucose-dependent insulin biosynthesis and secretion from β cells, creating a foundation for decades of research in the diabetes and obesity field. His work has revolutionized pharmaceutical developments that have offered enormous benefits for diabetes, obesity and short bowel syndrome.

Glucagon-like peptide-1 exerts peripheral and central actions that control metabolic pathways, appetite, body weight and glucose homeostasis. GLP-1 exerts its actions through a canonical receptor widely expressed in the islets, central and peripheral nervous system and in the heart. Notably, GLP-1R agonists approved for the treatment of diabetes have demonstrated cardiovascular safety, and in some instances, reduced cardiovascular death in outcome studies. This keynote will discuss relevant sites and mechanisms of GLP-1 action, with clinical implications for the treatment of metabolic disease.